Oragenics, Inc. Chief Medical Officer, Dr. James Kelly, Joins the Medical Board of The Leigh Steinberg Foundation for Concussion, Traumatic Brain Injury, and Brain Health
Oragenics (NYSE American: OGEN) announced that its Chief Medical Officer, Dr. James Kelly, has been appointed to the Medical Board of The Leigh Steinberg Foundation for Concussion, Traumatic Brain Injury, and Brain Health. Dr. Kelly, previously the founding director of the National Intrepid Center of Excellence at Walter Reed National Military Medical Center, brings extensive experience in brain injury research and treatment.
The appointment aligns with Oragenics' development of ONP-002, their novel intranasal treatment for concussion. As a board member, Dr. Kelly will collaborate with leading researchers and medical professionals to advance brain health education, innovative research, and improved care access. The Leigh Steinberg Foundation focuses on supporting research, raising awareness, and developing solutions for those affected by concussions and traumatic brain injuries.
Oragenics (NYSE American: OGEN) ha annunciato che il suo Chief Medical Officer, il Dr. James Kelly, è stato nominato membro del Consiglio Medico della Leigh Steinberg Foundation per le commozioni cerebrali, le lesioni cerebrali traumatiche e la salute cerebrale. Il Dr. Kelly, precedentemente direttore fondatore del National Intrepid Center of Excellence presso il Walter Reed National Military Medical Center, porta con sé una vasta esperienza nella ricerca e nel trattamento delle lesioni cerebrali.
La nomina è in linea con lo sviluppo da parte di Oragenics di ONP-002, il loro innovativo trattamento intranasale per le commozioni cerebrali. In qualità di membro del consiglio, il Dr. Kelly collaborerà con ricercatori e professionisti medici di spicco per promuovere l'educazione sulla salute cerebrale, la ricerca innovativa e il miglioramento dell'accesso alle cure. La Leigh Steinberg Foundation si concentra sul supporto alla ricerca, sulla sensibilizzazione e sullo sviluppo di soluzioni per coloro che sono colpiti da commozioni cerebrali e lesioni cerebrali traumatiche.
Oragenics (NYSE American: OGEN) anunció que su Director Médico, el Dr. James Kelly, ha sido nombrado miembro de la Junta Médica de la Fundación Leigh Steinberg para las conmociones cerebrales, lesiones cerebrales traumáticas y salud cerebral. El Dr. Kelly, anteriormente director fundador del Centro Nacional de Excelencia Intrepid en el Centro Médico Militar Nacional Walter Reed, aporta una amplia experiencia en investigación y tratamiento de lesiones cerebrales.
El nombramiento se alinea con el desarrollo por parte de Oragenics de ONP-002, su novedoso tratamiento intranasal para las conmociones cerebrales. Como miembro de la junta, el Dr. Kelly colaborará con investigadores y profesionales médicos líderes para avanzar en la educación sobre la salud cerebral, la investigación innovadora y la mejora del acceso a la atención. La Fundación Leigh Steinberg se centra en apoyar la investigación, crear conciencia y desarrollar soluciones para quienes se ven afectados por conmociones cerebrales y lesiones cerebrales traumáticas.
Oragenics (NYSE American: OGEN)는 최고 의료 책임자인 제임스 켈리 박사가 뇌진탕, 외상성 뇌 손상 및 뇌 건강을 위한 리 스타인버그 재단의 의료 위원회에 임명되었다고 발표했습니다. 켈리 박사는 이전에 월터 리드 국립 군 의료 센터의 국가 인트레피드 우수 센터의 창립 이사로서 뇌 손상 연구 및 치료에 대한 광범위한 경험을 가지고 있습니다.
이번 임명은 Oragenics가 개발 중인 뇌진탕에 대한 혁신적인 비강 치료제 ONP-002와 일치합니다. 켈리 박사는 이사로서 주요 연구자 및 의료 전문가들과 협력하여 뇌 건강 교육, 혁신적인 연구 및 개선된 치료 접근성을 증진할 것입니다. 리 스타인버그 재단은 뇌진탕 및 외상성 뇌 손상의 영향을 받는 사람들을 위한 연구 지원, 인식 제고 및 솔루션 개발에 중점을 두고 있습니다.
Oragenics (NYSE American: OGEN) a annoncé que son directeur médical, le Dr James Kelly, a été nommé membre du conseil médical de la Fondation Leigh Steinberg pour les commotions cérébrales, les lésions cérébrales traumatiques et la santé cérébrale. Le Dr Kelly, auparavant directeur fondateur du National Intrepid Center of Excellence au Walter Reed National Military Medical Center, possède une vaste expérience dans la recherche et le traitement des lésions cérébrales.
Cette nomination s'inscrit dans le cadre du développement par Oragenics de ONP-002, leur traitement intranasal novateur pour les commotions cérébrales. En tant que membre du conseil, le Dr Kelly collaborera avec des chercheurs et des professionnels de la santé de premier plan pour faire avancer l'éducation à la santé cérébrale, la recherche innovante et l'amélioration de l'accès aux soins. La Fondation Leigh Steinberg se concentre sur le soutien à la recherche, la sensibilisation et le développement de solutions pour ceux qui sont touchés par des commotions cérébrales et des lésions cérébrales traumatiques.
Oragenics (NYSE American: OGEN) gab bekannt, dass sein Chief Medical Officer, Dr. James Kelly, in das medizinische Gremium der Leigh Steinberg Foundation für Gehirnerschütterungen, traumatische Gehirnverletzungen und Gehirngesundheit berufen wurde. Dr. Kelly, der zuvor als Gründungsdirektor des National Intrepid Center of Excellence am Walter Reed National Military Medical Center tätig war, bringt umfassende Erfahrung in der Forschung und Behandlung von Gehirnverletzungen mit.
Die Ernennung steht im Einklang mit der Entwicklung von ONP-002 durch Oragenics, ihrer neuartigen intranasalen Behandlung für Gehirnerschütterungen. Als Vorstandsmitglied wird Dr. Kelly mit führenden Forschern und medizinischen Fachleuten zusammenarbeiten, um die Bildung im Bereich Gehirngesundheit, innovative Forschung und den Zugang zu verbesserten Behandlungsangeboten voranzutreiben. Die Leigh Steinberg Foundation konzentriert sich auf die Unterstützung von Forschung, die Sensibilisierung und die Entwicklung von Lösungen für Menschen, die von Gehirnerschütterungen und traumatischen Gehirnverletzungen betroffen sind.
- Strengthens company's position in brain health sector through CMO's appointment to prestigious foundation
- Validates company's development of ONP-002 intranasal concussion treatment
- None.
Insights
While Dr. Kelly's appointment to The Leigh Steinberg Foundation's Medical Board is a prestigious recognition, its immediate impact on Oragenics' business operations and stock value is The company, with a micro-cap valuation of
However, this appointment does offer several strategic advantages worth noting:
- The connection to the Leigh Steinberg Foundation, known for its influence in professional sports, could facilitate patient recruitment for clinical trials of ONP-002, potentially accelerating the development timeline.
- Dr. Kelly's background with the National Intrepid Center of Excellence provides a valuable bridge to military healthcare systems, opening possibilities for future research collaborations and funding opportunities in treating combat-related TBI.
- The appointment strengthens Oragenics' credibility in the neurology space, particularly important for a micro-cap biotech company developing novel therapeutics.
From an investor perspective, while this news demonstrates the company's ability to attract and retain top talent, it's important to note that the primary value drivers remain the clinical development of ONP-002 and the company's ability to secure adequate funding for its research programs. The appointment should be viewed as a positive but incremental development in Oragenics' broader strategy to establish itself in the concussion treatment market.
SARASOTA, Fla., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, proudly announces that its Chief Medical Officer, Dr. James Kelly, has been appointed to the Medical Board of The Leigh Steinberg Foundation for Concussion, Traumatic Brain Injury, and Brain Health.
The Leigh Steinberg Foundation is dedicated to advancing brain health by supporting research, raising awareness, and driving actionable solutions for those affected by concussions and traumatic brain injuries (TBI). Dr. Kelly’s appointment to the Medical Board reflects his leadership in brain injury research and treatment, reinforcing his influence in shaping the future of concussion care.
As a globally recognized expert in TBI and neurological health, Dr. Kelly has made pioneering contributions to the field. Before joining Oragenics as Chief Medical Officer, he served as the founding director of the National Intrepid Center of Excellence (NICoE) at Walter Reed National Military Medical Center, where he led advancements in diagnosing and treating brain injuries, particularly for military personnel. His extensive experience also includes working with athletes and individuals impacted by concussions, positioning him as a key advocate for improved care and research.
Janet Huffman, Interim Chief Executive Officer and Chief Financial Officer of Oragenics, expressed the company’s enthusiasm for Dr. Kelly’s appointment:
“We are thrilled to see Dr. Kelly recognized for his expertise and dedication to brain health. His leadership at Oragenics has been instrumental in driving the development of ONP-002, our novel intranasal treatment for concussion. His involvement with The Leigh Steinberg Foundation further aligns with our mission to advance brain injury treatment and improve patient outcomes.”
Leigh Steinberg, founder of The Leigh Steinberg Foundation, also welcomed Dr. Kelly’s appointment, highlighting the impact of his expertise and Oragenics’ innovative work in concussion treatment:
“Dr. James Kelly is a distinguished leader in traumatic brain injury research and care, and we are honored to have him join our Medical Board. His expertise and dedication to advancing brain health align with our commitment to reshaping the narrative around concussions and traumatic brain injuries. His leadership at Oragenics in developing an intranasal treatment for concussions represents a critical step toward turning breakthrough research into tangible solutions. By leveraging innovative approaches to treatment, we have the potential to enhance recovery and accessibility for athletes, military personnel, and individuals affected by brain injuries. We look forward to working with Dr. Kelly as he helps guide Oragenics in its mission to prioritize brain health and advance the future of concussion care.”
As a member of the Medical Board, Dr. Kelly will work alongside leading researchers, medical professionals, and advocates to drive forward initiatives in brain health education, innovative research, and improved access to care. His work with Oragenics and the foundation further underscores his dedication to revolutionizing concussion management and enhancing patient outcomes.
“I am honored to join The Leigh Steinberg Foundation’s Medical Board and contribute to its important mission of improving brain health and concussion care,” said Dr. James Kelly. “With greater awareness, research, and innovative treatment options, we can make a meaningful difference in the lives of those affected by TBI.”
Investor Contact
Rich Cockrell
404.736.3838
ogen@cg.capital
About Oragenics, Inc.
Oragenics, Inc. (NASDAQ: OGEN) is a clinical-stage biotechnology company focused on developing breakthrough treatments for neurological disorders. The company’s lead asset, ONP-002, is an innovative intranasal therapy designed to address the unmet medical need in concussion treatment. Oragenics is committed to pioneering new approaches in neuroscience to improve patient outcomes. For more information, visit www.oragenics.com.
About The Leigh Steinberg Foundation
The Leigh Steinberg Foundation for Concussion, Traumatic Brain Injury, and Brain Health is dedicated to advancing brain health through advocacy, research, and real-world solutions. Founded by legendary sports agent Leigh Steinberg, the foundation works to raise awareness, support groundbreaking studies, and develop better care strategies for individuals suffering from brain injuries, particularly in sports and military communities.
Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to, those described in our Form 10-K and other filings with the U.S. Securities and Exchange Commission. All information set forth in this press release is as of the date hereof. You should consider these factors in evaluating the forward-looking statements included in this press release and not place undue reliance on such statements. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, circumstances should change, except as otherwise required by law.
FAQ
What is the significance of Dr. James Kelly joining The Leigh Steinberg Foundation's Medical Board for OGEN?
What is Oragenics (OGEN) developing for concussion treatment?
What was Dr. James Kelly's role before joining Oragenics (OGEN)?
How will Dr. Kelly's appointment impact Oragenics' (OGEN) brain health initiatives?
